Dihexa
PNB-0408
Angiotensin IV–derived research compound that improved cognition in rats; no human trials.
Not FDA-approved. Preclinical. Not approved. FDA Category 2 bulk listing. This page describes research and public discussion; it is not a recommendation to use.
Overview
Dihexa was developed at Washington State University and reported to be extremely potent at enhancing synapse formation in rat models of dementia. A related compound (fosgonimeton) failed its phase 2/3 Alzheimer's trial.
Mechanism of action
Positive modulator of hepatocyte growth factor (HGF)/c-Met signaling, promoting dendritic spine formation.
Benefits & evidence ratings
Dosing
Doses show what has been studied or discussed — not guidance. Always follow your prescriber.
| Source | Dose | Frequency | Duration | Route |
|---|---|---|---|---|
Clinically studied C Preliminary research | None | — | — | — |
Clinical trials & studies
- Animal2014Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents (JPET)
Rat studies of Dihexa.
- Phase 32024Fosgonimeton in Alzheimer's — LIFT-AD
Related HGF modulator missed primary endpoint.
Safety
Side effects
- Unknown in humans
- Theoretical: c-Met activation is oncogenic in some cancers
Contraindications
- Cancer history
- Pregnancy
Interactions
- Unknown
Long-term safety
Unknown.
Regulatory status
Unapproved / research
Preclinical. Not approved. FDA Category 2 bulk listing.